Charles River, Boston in October for the TRIPLE/TARGETS meeting

With the AACR-NCI-EORTC molecular targets meeting (aka TARGETS for short) kicking off later today with a couple of education sessions and keynote talks, it’s time to put up our final preview on this conference.

Sometimes what starts out intending to be a short review ends up a much longer one because you discover there are an unexpected number of more intriguing compounds coming through biotech pipelines than you anticipated.

This is a good thing given today’s hostile market where raising money has become much more challenging of late. The health of the industry is very much driven by innovation from small, nimble biotechs producing intriguing products and new ways of doing things.

I’m delighted to say we found quite a few of these examples this year that break the cycle of the humdrum same old, same old trend.

In the first review we highlighted a number of key topics relating to KRAS, HRAS, and other areas.

In this latest version we explore and discuss over a dozen topics relating to DNA damage response (DDR), epigenetics, synthetic lethality and others.

In fact, I will go as far as to say a few of the class of 2023 may well stand out for years to come if all goes to plan in the clinic, although they are unlikely to be the more obvious examples I’ve seen touted lately…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by